Recent Vanderbilt University patents describe metabotropic glutamate mGlu5 receptor negative allosteric modulators reported to be useful for the treatment of amyotrophic lateral sclerosis, Angelman syndrome, anxiety disorder, autism spectrum disorders, substance abuse and dependence, Alzheimer’s disease, diabetes and obesity, among others.